

University of Mississippi

eGrove

Honors Undergraduate Research Poster
Symposium

Honors College (Sally McDonnell Barksdale
Honors College)

3-3-2023

Developmental exposure to minor cannabinoids causes morphological and behavioral adverse outcomes in zebrafish larvae

Marissa J. Skulsky
University of Mississippi

Cammi Thornton
University of Mississippi

Jason Paris
University of Mississippi

Kristine L. Willett
University of Mississippi

Follow this and additional works at: https://egrove.olemiss.edu/hon_posters


Recommended Citation

Skulsky, Marissa J.; Thornton, Cammi; Paris, Jason; and Willett, Kristine L., "Developmental exposure to minor cannabinoids causes morphological and behavioral adverse outcomes in zebrafish larvae" (2023). *Honors Undergraduate Research Poster Symposium*. 8.
https://egrove.olemiss.edu/hon_posters/8

This Book is brought to you for free and open access by the Honors College (Sally McDonnell Barksdale Honors College) at eGrove. It has been accepted for inclusion in Honors Undergraduate Research Poster Symposium by an authorized administrator of eGrove. For more information, please contact egrove@olemiss.edu.

Developmental exposure to minor cannabinoids causes morphological and behavioral adverse outcomes in zebrafish larvae

Marissa J. Skulsky, Cammi Thornton, Jason Paris, and Kristine L. Willett
University of Mississippi, University, MS




Introduction

- Minor cannabinoids are naturally occurring minor components of the cannabis plant.
- With recent large-scale legalizations of cannabis for recreational use, minor cannabinoids have become increasingly used.
- Cannabinoids are even marketed to pregnant women to relieve symptoms, but there is little research in their safety for a developing fetus.

Objectives

- Determine if minor cannabinoid exposure results in adverse morphological and behavioral effects in developing zebrafish as was previously measured following THC and CBD exposures
- Understand relative potency of the different cannabinoids for developmental toxicities

Methods



Δ8-Tetrahydrocannabinol (Δ8THC) and Tetrahydrocannabivarin (THCV) Results




Figure 1A-B: Distance traveled by Δ8THC (1A) and THCV (1B) treated fish over 50 min (0-10 min acclimation, 10-20 and 30-40 min dark, 20-30 and 40-50 min light). Δ8THC (2 μM) and THCV (0.12, 0.5, and 2 μM) treated fish were hypoactive during the light (Δ8THC) and dark phases (Δ8THC and THCV).




Figure 1C: Δ8THC (2 μM) and THCV (0.12, 0.5, and 2 μM) treated fish had significant (*) hypoactivity compared to the controls (ANOVA on ranks; Dunn's posthoc test; *p<0.05).

Cannabigerol (CBG) and Cannabinol (CBN) Results




Figure 2A-B: Distance traveled by CBG (2A) and CBN (2B) treated fish over 50 min (0-10 min acclimation, 10-20 and 30-40 min dark, 20-30 and 40-50 min light). Behavior of treated fish did not significantly deviate from the control fish.




Figure 2C: Neither CBG nor CBN exposure caused significant effects on larval behavior during the dark phase (2C), light phase or acclimation phase (data not shown; ANOVA on ranks).

Results

Mortality:

- All four of the minor cannabinoids were 100% lethal at the highest concentration of 8 μM: THCV and CBG at 48 hpf; and Δ8THC and CBN at 96 hpf.

Morphological Changes:

- While present in some fish, adverse morphological changes were not statistically significant compared to control-treated fish.

Behavioral Changes:

- Behavior was significantly altered following Δ8THC and THCV exposure (Figure 1) but not CBG or CBN exposure (Figure 2).

Conclusions

- These results suggest exposure to minor cannabinoids can, like Δ9-THC and CBD, cause significant behavioral changes in developing zebrafish.
- Differences between cannabinoid effects could be attributed to differences in chemical structure, bioavailability, and/or cannabinoid receptor 1 and 2 binding affinities (Table 1).
- The human relevance of developing toxicity of minor cannabinoids needs further consideration.

Table 1: The cannabinoids that have been (bolded) will be screened in this study including abbreviations and representative CB1 Ki (nM) and affinity (unk = unknown).

Cannabinoid	CB1 Ki	Affinity	Ref
Δ9-tetrahydrocannabinol	THC 18	agonist	1
Cannabidiol	CBD 151	weak agonist	1
Δ8-tetrahydrocannabinol	8-THC 78	partial agonist	1
Tetrahydrocannabivarin	THCV 22	antagonist	1
Cannabigerol	CBG 3090	partial agonist	1
Cannabinol	CBN 75	agonist	1
Cannabidiolic acid	CBDA 626	Agonist/antagonist	2
Tetrahydrocannabinolic acid	THCA 1292	+ allosteric mod	1
THC acetate ester	THCO unk		
Tetrahydrocannabiphoriol	THCP 1.2	agonist	3
αHexahydrocannabinol	HHC 117	agonist	1
Δ10-tetrahydrocannabinol	10-THC unk		

1. Husni AS, et al. *Med Chem Res.* 2014;23(9):4295-4300.
2. Navarro G, et al. *Pharmacol Res.* 2020;159(May):104940.
3. Citti C, et al. *Sci Rep.* 2019;9(1):1-13.

Future Experiments

- Six more minor cannabinoids (CBDA, THCA, THCO, and THCP, Δ10THC, and HHC) will be tested for behavioral and morphological adverse outcomes.
- We will also determine cannabinoid exposure impacts on brain mitochondrial energetics.